Pediatric Seronegative NMOSD: A Case Series and Literature Review
Madison Patrick1, Arjith Rathakrishnan2, Vikram Prakash3
1Orlando Regional Campus, Florida State University College of Medicine, 2Pediatric Residency Program, 3Leon Pediatric Neuroscience Center of Excellence, Department of Pediatric Neurology, Arnold Palmer Hospital
Objective:

Clinical presentation and course of three pediatric Neuromyelitis Optica Spectrum Disorder (NMOSD) cases with negative aquaporin-4 (AQP4) IgG antibodies (seronegative).

Background:

NMOSD is an autoimmune disorder characterized by chronic, relapsing episodes of inflammation primarily affecting the spinal cord, optic nerves, and brainstem. Less than 5% of cases occur in pediatric patients, with almost all being AQP4-IgG positive. Diagnosis of the few seronegative cases relies heavily on clinical presentation. Myelin oligodendrocyte (MOG) IgG is often positive in this patient group; double seronegative (AQP4-IgG and MOG-IgG) cases are not well described.

Design/Methods:

Chart review identified three cases of seronegative NMOSD diagnosed between 2018-2023.

Results:

Patients 1 and 2 presented before three years of age and patient 3 at 15 years of age. Patient 1 exhibited typical NMOSD optico-spinal disease with relapses over five years of follow up; MRI showed lumbar spinal root enhancement. Patient 2 presented with altered sensorium, vision loss, and left leg weakness; MRI demonstrated diencephalic and central spinal cord lesions suggestive of NMOSD. Patient 3 presented with area postrema syndrome and had subsequent relapses of brainstem syndrome manifesting as trigeminal neuralgia and cranial nerve palsies. AQP4-IgG was negative in all patients. MOG-IgG was positive in patient 2 (1:40) and 3 (1:20); patient 3 tested negative three months later, as expected with low titers.

Conclusions:

Pediatric NMOSD has typical features and a course that parallels adult NMOSD. Lumbar root enhancement in NMOSD is an atypical feature without MOG-IgG positivity. Low titers of MOG-IgG should not rule out NMOSD, (demonstrated by patient 3), which is a more aggressive disease with higher relapse risk and incomplete relapse recovery. Differentiating between negative and possibly false positive (low titer) MOG-IgG in NMOSD can difficult early on, (as shown by patient 2), but is needed for expeditious initiation of immunomodulatory therapy to prevent further relapses and permanent neurological deficits.

10.1212/WNL.0000000000205839